CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis

Affiliations

¹ Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany.
² Amgen Research (Munich) GmbH, Munich, Germany.
³ Scientific Directorate, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
⁴ Amgen Inc., Thousand Oaks, California, USA.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Free article

Heinz-August Horst et al. Am J Hematol. 2023 Aug.

Free article

. 2023 Aug;98(8):E222-E225.

doi: 10.1002/ajh.26988. Epub 2023 Jun 22.

¹ Department of Internal Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany.
² Amgen Research (Munich) GmbH, Munich, Germany.
³ Scientific Directorate, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
⁴ Amgen Inc., Thousand Oaks, California, USA.
⁵ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

No abstract available

References

1. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836-847.
1. Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35(16):1795-1802.
1. Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020;135(11):804-813.
1. Mejstrikova E, Klinger M, Markovic A, Zugmaier G, Locatelli F. CD19 expression in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia pre- and post-treatment with blinatumomab. Pediatr Blood Cancer. 2021;68(12):e29323.
1. Jabbour E, Düll J, Yilmaz M, et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol. 2018;93(3):371-374.